Novavax - NVAX Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVAX, but not buy additional shares or sell existing shares.
View NVAX analyst ratings or view top-rated stocks.

7 brokers have issued 12 month price objectives for Novavax's shares. Their NVAX share price forecasts range from $27.00 to $207.00. On average, they anticipate the company's share price to reach $128.25 in the next twelve months. This suggests a possible upside of 604.7% from the stock's current price.
View analysts price targets for NVAX or view top-rated stocks among Wall Street analysts.

Novavax's stock was trading at $143.07 at the beginning of 2022. Since then, NVAX shares have decreased by 87.3% and is now trading at $18.20.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NVAX earnings forecast.

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings results on Monday, August, 8th. The biopharmaceutical company reported ($6.53) EPS for the quarter, missing analysts' consensus estimates of $5.51 by $12.04. The biopharmaceutical company had revenue of $186 million for the quarter, compared to analysts' expectations of $1.02 billion. Novavax had a negative trailing twelve-month return on equity of 572.54% and a negative net margin of 114.32%. The business's revenue was down 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($4.75) earnings per share.

Shares of Novavax reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Novavax issued an update on its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.00 billion-$2.30 billion, compared to the consensus revenue estimate of $4.27 billion.

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $18.20.

Novavax (NASDAQ:NVAX) has a market capitalization of $1.42 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($19.46) on an earnings per share basis.

The company employs 1,541 workers across the globe.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.